{"id":34192,"date":"2026-03-18T05:54:06","date_gmt":"2026-03-18T05:54:06","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/34192\/"},"modified":"2026-03-18T05:54:06","modified_gmt":"2026-03-18T05:54:06","slug":"roche-secures-ce-mark-for-blood-test-to-identify-apoe4-carriers","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/34192\/","title":{"rendered":"Roche secures CE mark for blood test to identify ApoE4 carriers"},"content":{"rendered":"<p>Roche Holding AG received CE Mark approval for its Elecsys Apolipoprotein E4 (ApoE4) biomarker test, an in vitro diagnostic immunoassay to identify the ApoE4 gene variant from a blood sample. With APOE4 considered as the strongest genetic risk factor for developing Alzheimer\u2019s disease, the test provides a fast, reliable way to determine whether an individual carries the genetic variant without the need for DNA\u2011based genotyping.<\/p>\n<p><a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/84-bioworld\" rel=\"nofollow noopener\" target=\"_blank\">BioWorld<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/85-medical-technology\" rel=\"nofollow noopener\" target=\"_blank\">Medical technology<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/402-regulatory\" rel=\"nofollow noopener\" target=\"_blank\">Regulatory<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/325-diagnostics\" rel=\"nofollow noopener\" target=\"_blank\">Diagnostics<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/256-neurology-psychiatric\" rel=\"nofollow noopener\" target=\"_blank\">Neurology\/psychiatric<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/396-europe\" rel=\"nofollow noopener\" target=\"_blank\">Europe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Roche Holding AG received CE Mark approval for its Elecsys Apolipoprotein E4 (ApoE4) biomarker test, an in vitro&hellip;\n","protected":false},"author":2,"featured_media":34193,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[15909,19950,8086,15910,1176,8555,20237,197,9063,20238,4180,134,473],"class_list":["post-34192","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-alzheimers-disease","tag-apoe4","tag-bioworld","tag-dementia","tag-diagnostics","tag-elecsys","tag-elecsys-apolipoprotein-e4","tag-europe","tag-medical-technology","tag-neurology-psychiatric","tag-regulatory","tag-roche","tag-roche-holding-ag"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116248632511439760","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/34192","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=34192"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/34192\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/34193"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=34192"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=34192"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=34192"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}